Workflow
无锡药明康德新药开发股份有限公司关于调整回购股份价格上限的公告
Shang Hai Zheng Quan Bao·2025-07-29 17:36

Core Viewpoint - The company has adjusted the upper limit for the repurchase price of its shares from 90.72 RMB to 114.15 RMB per share, reflecting confidence in its future development and the recognition of its value [1][4]. Group 1: Basic Situation of Share Repurchase - The company received general authorization from the shareholders' meetings held on April 29, 2025, to repurchase A-shares and/or H-shares [2]. - The total amount allocated for the repurchase is 1 billion RMB, with a repurchase period not exceeding 12 months from the approval date [2]. Group 2: Progress of Share Repurchase - As of July 28, 2025, the company has repurchased a total of 6,514,425 A-shares, accounting for 0.23% of the total share capital, with an average repurchase price of 76.34 RMB per share [3]. Group 3: Specifics of Price Adjustment - The adjustment of the repurchase price limit to 114.15 RMB per share is based on the average trading price of the company's shares over the previous 30 trading days, set at 150% of that average [4]. Group 4: Impact of Price Adjustment - The adjustment complies with relevant regulations and is expected to facilitate the smooth implementation of the repurchase plan without adversely affecting the company's operations, financial status, or future development [5][6].